Literature DB >> 19187062

Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR.

S Martignago1, M Fanin, E Albertini, E Pegoraro, C Angelini.   

Abstract

AIMS: We compared myopathological features in myasthenia gravis (MG) patients with antibodies against AChR (seropositive) and muscle-specific tyrosin-kinase (MuSK). While the immunopathogenesis of seropositive MG is well known, there is a lack of pathological studies in anti-MuSK antibody-positive (MuSK+) MG.
METHODS: We analysed skeletal muscle biopsy features of 13 MG patients: 6 MuSK+ (all women) and 7 anti-AchR antibody-positive (AChR+) (2 women and 5 men). In our histopathological examination, we quantified the atrophy factor of both fibre types, and the extent of minicores, myofibrillar disarray, cytochrome c oxidase (COX)-negative fibres, mitochondrial aggregates and fibre type grouping.
RESULTS: Mean muscle fibre atrophy factor was higher in AChR+ MG than MuSK+ MG, both in type I fibres (494 vs. 210) and particularly in type II fibres (1023 vs. 300). Fibre type grouping was observed in AChR+ MG whereas COX-negative fibres were common in MuSK+ MG. Bulbar muscles were more severely affected in MuSK+ MG and the disease was more severe: the onset was usually earlier (39 years) with Myasthenia Gravis Foundation of America score III in MuSK+ MG, and score II was found in AChR+ MG (62 years).
CONCLUSIONS: Muscle biopsies of MuSK+ MG show myopathic signs with prominent mitochondrial abnormalities, whereas neurogenic features and atrophy are more frequently found in AChR+ MG. The mitochondrial impairment could explain the oculo-bulbar involvement in MuSK+ MG.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19187062     DOI: 10.1111/j.1365-2990.2008.00965.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  16 in total

Review 1.  Diagnosis and management of autoimmune myasthenia gravis.

Authors:  Corrado Angelini
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 2.  Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Authors:  Michael H Rivner; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; Lin Mei
Journal:  Neurol Clin       Date:  2018-05       Impact factor: 3.806

3.  Diagnostic evaluation of rhabdomyolysis.

Authors:  Jessica R Nance; Andrew L Mammen
Journal:  Muscle Nerve       Date:  2015-03-14       Impact factor: 3.217

4.  Animal models of antimuscle-specific kinase myasthenia.

Authors:  David P Richman; Kayoko Nishi; Michael J Ferns; Joachim Schnier; Peter Pytel; Ricardo A Maselli; Mark A Agius
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

5.  Comparison of muscle ultrastructure in myasthenia gravis with anti-MuSK and anti-AChR antibodies.

Authors:  Giovanna Cenacchi; Valentina Papa; Papa Valentina; Marina Fanin; Fanin Marina; Elena Pegoraro; Pegoraro Elena; Corrado Angelini; Angelini Corrado
Journal:  J Neurol       Date:  2010-11-19       Impact factor: 4.849

6.  Radiological Characteristics of Extraocular Muscles in Myasthenia Gravis Patients with Ocular Manifestations: A Case-Control Study.

Authors:  Sirin Lueangaram; Oranan Tritanon; Sukanya Siriyotha; Kavin Vanikieti; Tanyatuth Padungkiatsagul; Pisit Preechawat; Anuchit Poonyathalang; Charungthai Dejthevaporn; Teeratorn Pulkes; Supoch Tunlayadechanont; Panitha Jindahra
Journal:  Clin Ophthalmol       Date:  2021-06-01

Review 7.  The mitochondrial biogenesis signaling pathway is a potential therapeutic target for myasthenia gravis via energy metabolism (Review).

Authors:  Lingling Ke; Qing Li; Jingwei Song; Wei Jiao; Aidong Ji; Tongkai Chen; Huafeng Pan; Yafang Song
Journal:  Exp Ther Med       Date:  2021-05-02       Impact factor: 2.447

8.  Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status.

Authors:  Shin Joong Oh
Journal:  J Clin Neurol       Date:  2009-06-30       Impact factor: 3.077

Review 9.  New treatments for myasthenia: a focus on antisense oligonucleotides.

Authors:  Corrado Angelini; Sara Martignago; Michela Bisciglia
Journal:  Drug Des Devel Ther       Date:  2013-01-10       Impact factor: 4.162

10.  Fatigue and muscle atrophy in a mouse model of myasthenia gravis is paralleled by loss of sarcolemmal nNOS.

Authors:  Sarina Meinen; Shuo Lin; Markus A Rüegg; Anna Rostedt Punga
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.